DE3634671A1 - Antirheumatic agents with reduced toxicity - Google Patents
Antirheumatic agents with reduced toxicityInfo
- Publication number
- DE3634671A1 DE3634671A1 DE19863634671 DE3634671A DE3634671A1 DE 3634671 A1 DE3634671 A1 DE 3634671A1 DE 19863634671 DE19863634671 DE 19863634671 DE 3634671 A DE3634671 A DE 3634671A DE 3634671 A1 DE3634671 A1 DE 3634671A1
- Authority
- DE
- Germany
- Prior art keywords
- tryptophan
- methionine
- reduced toxicity
- antirheumatic agents
- capsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Es ist allgemein bekannt, daß die Antirheumatika oft über lange Zeiträume eingenommen werden müssen. Sie entfalten dementsprechend auch unerwünschte Nebenwirkungen, die im Laufe der Zeit zu gefähr lichen chronischen Krankheitszuständen führen können. So sind Nebenwirkungen von dem viel verwendeten Aspirin bekannt, die lebensbedrohend sind. Auch treten gefahrvolle Nebenerscheinungen nach Dauereinnahme von Indomethacin, Penicillamin und von Gold präparaten, wie dem Auranofin u. a. auf.It is well known that the anti-inflammatory drugs are often long-lasting Periods must be taken. They unfold accordingly also undesirable side effects that become dangerous over time chronic chronic disease. So are Known side effects from the much used aspirin, the are life threatening. There are also dangerous side effects after continuous intake of indomethacin, penicillamine and gold preparations such as the Auranofin u. a. on.
Es sind zahlreiche Bemühungen unternommen worden, durch Änderung der Konstitution den chemischen Substanzen die unerwünschten Nebenwirkungen zu nehmen. Doch bisher waren alle Versuche wenig erfolgreich.Numerous efforts have been made through change the constitution of chemical substances undesirable To take side effects. So far, however, all attempts have been few successful.
Nun wurde die überraschende Beobachtung gemacht, daß die Amino säuren L-Methionin und L-Tryptophan, zusammen mit Antirheumatika verabreicht, einen sehr günstigen Einfluß auf die Eliminierung unerwünschter Nebenwirkungen besitzen. Zwar ist bei verschiedenen Leberleiden oft von einer protektiven Wirkung gewisser Amino säuren berichtet worden, so in OS-PS 20 13 026 von Leucin, Isoleucin, Lysin, Phenylalanin und/oder Tryptophan; aminosäurehaltige Infu sionslösungen sind zur Behandlung von schweren Leberinsuffizienzen vorgeschlagen worden (OS-PS 29 44 341).Now the surprising observation has been made that the amino acids L-methionine and L-tryptophan, along with anti-inflammatory drugs administered, a very favorable influence on the elimination have undesirable side effects. Although at different Liver disorders often have a protective effect of certain amino acids acids have been reported, for example in OS-PS 20 13 026 of leucine, isoleucine, Lysine, phenylalanine and / or tryptophan; amino acid infu Solutions are for the treatment of severe liver insufficiency have been proposed (OS-PS 29 44 341).
In Tabelle 1 ist der Einfluß verschiedener Antirheumatika auf die Leber aufgezeigt an Hand verschiedener Enzymaktivitäten. Allgemein ist es anerkannt, daß die Serum-Enzyme Glutamat-Oxylat- Transaminasen (GOT) und Glutamat-Pyroxal-Transaminase (GPT) bei Schädigung der Leber ansteigen. Von unserem Arbeitskreis wurde beobachtet, daß die Aktivität der Tyrosin-Aminotransferase (TAT) durch eine Reihe von Substanzen erhöht werden kann. Hierbei handelt es sich um das erste Enzym des Tyrosin-Abbaus.Table 1 shows the influence of various anti-inflammatory drugs the liver is shown using various enzyme activities. It is generally accepted that the serum enzymes glutamate oxylate Transaminases (GOT) and glutamate pyroxal transaminase (GPT) Liver damage increase. From our working group observed that the activity of tyrosine aminotransferase (TAT) can be increased by a number of substances. Here it is the first enzyme to break down tyrosine.
Im Verlaufe der Leberschädigung ist auch die Aktivität des Enzyms Adenosindiphosphatribose-Transferase (ADPR-Transferase) erhöht. Dieses Enzym überträgt unter Spaltung von NAD ADPR auf das Pro tein. Die Folge ist eine Konformations-Änderung des Proteins. Dadurch wird eine Regulation ermöglicht. The activity of the enzyme is also in the course of liver damage Adenosine diphosphatribose transferase (ADPR transferase) increased. This enzyme transfers ADPR to the Pro by cleaving NAD complexion. The result is a change in the conformation of the protein. This enables regulation.
Eine deutliche Zunahme der Aktivitäten von GOT, GPT und TAT kann beobachtet werden bei der Gabe von Aspirin, Auranofin, Indomethacin und Diclofenac. Hierbei kommt es teilweise auch zu einer Zunahme der ADPR-Transferase-Aktivität. Gleichzeitige Gabe von Methionin und Tryptophan verhindert diese Zunahme beträchtlich.A significant increase in the activities of GOT, GPT and TAT can be observed when aspirin, auranofin, Indomethacin and diclofenac. This also happens in part to an increase in ADPR transferase activity. Simultaneously Administration of methionine and tryptophan prevents this increase considerably.
Unsere Versuchsanordnung zeigt:
L-Methionin und L-Tryptophan wurden zu gleichen Teilen miteinander
gemischt und verrieben. Von dieser Metryphan genannten Mischung
erhielten Ratten 600 mg/kg intraperitoneal verabreicht.
Die antirheumatischen Substanzen wurden in den in Tabelle 1
angegebenen Dosen intraperitoneal zusammen mit dem Metryphan
verabreicht. Die Tiere wurden nach drei Stunden getötet. Die
GOT und GPT wurden nach H. U. Bergmeyer (Methoden der enzyma
tischen Analyse Bd. I, S 492, Verlag Chemie, 1974), Tyrosin-
Amino-Transferase (TAT) nach H. Kröger und Mitarb. (Biochem. Z.
341, 190, 1965) und ADPR-Transferase nach R. R. Kidwell und Mitarb.
(Biochem. Biophys. Res. Commun. 61, 766, 1974) bestimmt.
Dimethylsulfoxyd wurde 1 : 2 verdünnt mit 0,1 M NaCl; 0,15 M NaCl
diente als Kontrolle. Tabelle 1 zeigt die Ergebnisse.Our experimental setup shows:
L-methionine and L-tryptophan were mixed in equal parts and triturated. Rats received 600 mg / kg intraperitoneally from this mixture called Metryphan. The antirheumatic substances were administered intraperitoneally together with the metryphan in the doses indicated in Table 1. The animals were sacrificed after three hours. The GOT and GPT were according to HU Bergmeyer (methods of enzymatic analysis vol. I, S 492, Verlag Chemie, 1974), tyrosine amino transferase (TAT) according to H. Kröger and Mitarb. (Biochem. Z. 341, 190, 1965) and ADPR transferase according to RR Kidwell and Mitarb. (Biochem. Biophys. Res. Commun. 61, 766, 1974). Dimethyl sulfoxide was diluted 1: 2 with 0.1 M NaCl; 0.15 M NaCl served as a control. Table 1 shows the results.
Um welchen genaueren Mechanismus es sich bei dieser eindeutigen Wirkung handelt, und zwar bei der Vielzahl der Verschieden heit chemischer Konstitutionen, soll noch eine offene Frage bleiben.What more precise mechanism is this unique Effect acts, and that with the multitude of different of chemical constitutions should still be an open question stay.
Metryphan kann in Form von Tabletten, Kapseln, Dragees, Tropfen, Sirups und dergleichen direkt mit den antirheumatischen Körpern verabreicht werden oder auch gesondert.Metryphan can be in the form of tablets, capsules, coated tablets, drops, Syrups and the like directly with the anti-rheumatic bodies be administered or separately.
In Tabelle 2 aufgezeigte Beispiele sollen die Ausführung der Erfindung zeigen. Examples shown in Table 2 are intended to implement the Show invention.
Azetylsalicylsäure 400 mg L-Methionin 200 mg L-Tryptophan 200 mg Tablettenhilfsmittel, ad.1000 mg Acetylsalicylic acid 400 mg L-methionine 200 mg L-tryptophan 200 mg tablet excipients, ad.1000 mg
Tablettenherstellung in konventioneller Weise zu 1 g.Tablet production in a conventional manner at 1 g.
Diclofenac-Natrium 25 mg L-Methionin 200 mg L-Tryptophan 200 mgDiclofenac sodium 25 mg L-methionine 200 mg L-tryptophan 200 mg
Die Bestandteile werden gemischt und in konventioneller Weise in Kapseln gefüllt.The ingredients are mixed and in a conventional manner filled in capsules.
Auranofin 3 mg L-Methionin 100 mg L-Tryptophan 100 mgAuranofin 3 mg L-methionine 100 mg L-tryptophan 100 mg
Bestandteile werden gemischt, granuliert nach konventioneller Art und in Kapseln gebracht.Ingredients are mixed, granulated in the conventional way and in Capsules brought.
Natriumgentiat 90 mg L-Methionin 150 mg L-Tryptophan 150 mgSodium gentiate 90 mg L-methionine 150 mg L-tryptophan 150 mg
werden in konventioneller Weise zu Dragees von 500 mg verarbeitetare processed in a conventional manner to 500 mg coated tablets
Indometacin 50 mg L-Methionin 100 mg L-Tryptophan 100 mgIndomethacin 50 mg L-methionine 100 mg L-tryptophan 100 mg
Kapseln nach konventioneller Art.Capsules the conventional way.
Ibuprofen 400 mg L-Methionin 200 mg L-Tryptophan 200 mgIbuprofen 400 mg L-methionine 200 mg L-tryptophan 200 mg
Kapseln nach konventioneller Art.Capsules the conventional way.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19863634671 DE3634671A1 (en) | 1986-10-09 | 1986-10-09 | Antirheumatic agents with reduced toxicity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19863634671 DE3634671A1 (en) | 1986-10-09 | 1986-10-09 | Antirheumatic agents with reduced toxicity |
Publications (1)
Publication Number | Publication Date |
---|---|
DE3634671A1 true DE3634671A1 (en) | 1988-05-19 |
Family
ID=6311533
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE19863634671 Withdrawn DE3634671A1 (en) | 1986-10-09 | 1986-10-09 | Antirheumatic agents with reduced toxicity |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE3634671A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3912232A1 (en) * | 1989-04-11 | 1989-11-30 | Klosa Josef | Remedy for urinary incontinence |
EP1978408A1 (en) | 2007-03-29 | 2008-10-08 | FUJIFILM Corporation | Negative resist composition and pattern forming method using the same |
WO2009063824A1 (en) | 2007-11-14 | 2009-05-22 | Fujifilm Corporation | Method of drying coating film and process for producing lithographic printing plate precursor |
EP2105690A2 (en) | 2008-03-26 | 2009-09-30 | Fujifilm Corporation | Method and apparatus for drying |
WO2013015121A1 (en) | 2011-07-27 | 2013-01-31 | 富士フイルム株式会社 | Photosensitive composition, master plate for planographic printing plate, polyurethane, and method for producing polyurethane |
WO2015064602A1 (en) | 2013-10-31 | 2015-05-07 | 富士フイルム株式会社 | Laminate, organic-semiconductor manufacturing kit, and resist composition for manufacturing organic semiconductor |
US11848249B2 (en) | 2019-09-26 | 2023-12-19 | Fujifilm Corporation | Manufacturing method for thermal conductive layer, manufacturing method for laminate, and manufacturing method for semiconductor device |
-
1986
- 1986-10-09 DE DE19863634671 patent/DE3634671A1/en not_active Withdrawn
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3912232A1 (en) * | 1989-04-11 | 1989-11-30 | Klosa Josef | Remedy for urinary incontinence |
EP1978408A1 (en) | 2007-03-29 | 2008-10-08 | FUJIFILM Corporation | Negative resist composition and pattern forming method using the same |
WO2009063824A1 (en) | 2007-11-14 | 2009-05-22 | Fujifilm Corporation | Method of drying coating film and process for producing lithographic printing plate precursor |
EP2105690A2 (en) | 2008-03-26 | 2009-09-30 | Fujifilm Corporation | Method and apparatus for drying |
WO2013015121A1 (en) | 2011-07-27 | 2013-01-31 | 富士フイルム株式会社 | Photosensitive composition, master plate for planographic printing plate, polyurethane, and method for producing polyurethane |
WO2015064602A1 (en) | 2013-10-31 | 2015-05-07 | 富士フイルム株式会社 | Laminate, organic-semiconductor manufacturing kit, and resist composition for manufacturing organic semiconductor |
US11848249B2 (en) | 2019-09-26 | 2023-12-19 | Fujifilm Corporation | Manufacturing method for thermal conductive layer, manufacturing method for laminate, and manufacturing method for semiconductor device |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0874618B1 (en) | Preparation for improving hair growth, the skin structure and/or nail regeneration | |
Taghzouti et al. | Alternation behavior, spatial discrimination, and reversal disturbances following 6-hydroxydopamine lesions in the nucleus accumbens of the rat | |
Otten et al. | Selective induction of tyrosine hydroxylase and dopamine β-hydroxylase by nerve growth factor: comparison between adrenal medulla and sympathetic ganglia of adult and newborn rats | |
EP0210204B1 (en) | Protein hydrolysates, production process and drugs containing th em | |
DE69933738T2 (en) | Composition containing amino acids and trehalose | |
JPH02501065A (en) | Methods and compositions for treating obesity, depression, drug abuse and narcolepsy | |
DE3206784A1 (en) | AMINO ACID PREPARATIONS CONTAINING GLUTAMINE | |
DE3634671A1 (en) | Antirheumatic agents with reduced toxicity | |
DE69935140T2 (en) | USE OF ANABOLIKA, ANTI-CATABOLIC AGENTS, ANTIOXIDANTS AND ANALGETICS FOR THE PROTECTION, TREATMENT AND REPAIR OF BINDING WEBTS IN HUMANS AND ANIMALS | |
CH678918A5 (en) | ||
EP0516594A1 (en) | L-carnitine derivatives as therapeutical agents for treating myopathies and neuronal degeneration and for inhibiting proteolysis | |
DE3223150C2 (en) | ||
Morehead et al. | Renal injury in the rat following the administration of serine by stomach tube | |
EP0714276B1 (en) | Composition against hair loss and brittle nails | |
DE4211239C2 (en) | Medicines for cardiovascular diseases | |
CA2283122A1 (en) | Plant extract compositions, method of preparation, and pharmaceutical compositions containing them | |
WO1998008511A1 (en) | Use of 2-phenyl-1, 2-benzisoselenazol-3(2h)-one for producing a pharmaceutical preparation intended for treatment of the alzheimer's disease | |
Tong et al. | Role of cyclic GMP in the mediation of circadian rhythmicity of the adenylate cyclase-cyclic AMP-phosphodiesterase system in Euglena | |
DE69332947T2 (en) | MEDICINAL PRODUCT CONTAINING 2- (3-BENZOYLPHENYL) -PROPIONIC ACID FOR USE AS AN ANALGETIC | |
DE69533742T2 (en) | Use of proline and / or derivatives as anti-hepatitis agents | |
FR2511597A1 (en) | PRODUCTS EXTRACTED FROM MARINE INVERTEBRATES, THEIR PREPARATION AND THEIR APPLICATIONS IN DIETETICS AND COSMETOLOGY | |
Reingold et al. | INHIBITION OF BRAIN GLUTAMATE DECARBOXYLASE BY 2‐KETO‐4‐PENTENOIC ACID, A METABOLITE OF ALLYLGLYCINE 1 | |
Imperato et al. | Benzodiazepines prevent kainate-induced loss of GABAergic and cholinergic neurons in the chick retina | |
DE2803397A1 (en) | BIOLOGICALLY ACTIVE SUBSTANCE, METHOD FOR THE PRODUCTION THEREOF AND MEANS CONTAINING THE SAME | |
King et al. | Cocaine and amphetamine modification of cerebral energy metabolism in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8139 | Disposal/non-payment of the annual fee |